title: Changes in purine levels and adenosine receptors in kindled seizures in the rat.
abstract: Adenosine is an inhibitory modulator of neuronal activity and its possible involvement in seizures is of interest. We have examined changes in adenosine, its metabolites and receptors in brains of hippocampus-kindled rats, a model of partial epilepsy. Purine levels were measured by in vivo microdialysis and showed a small increase in adenosine and a dramatic increase in its metabolites after kindled seizures. Adenosine A1 receptor binding using [H]DPCPX was unaltered after seizures, whereas A1 agonist stimulated binding of GTP[gamma-S] and A1 mRNA expression increased in the CA3 and other regions. Striatal adenosine A2A mRNA and receptor binding with [H]SCH-58261 decreased. These findings indicate that kindled seizures increase adenosine release and metabolism and induces adaptive changes in adenosine receptors.
authors.affiliation: Department of Woman and Child Health, Karolinska Institutet, S-171 76 Stockholm, Sweden. ulrika.aden@fyfa.ki.se
authors.forename: Ulrika
authors.initials: U
authors.lastname: Adén
authors.forename: William T
authors.initials: WT
authors.lastname: O'Connor
authors.forename: Robert F
authors.initials: RF
authors.lastname: Berman
mesh_terms: D000818:Animals; D001345:Autoradiography; D001665:Binding Sites / Q000187:drug effects / Q000502:physiology; D001923:Brain Chemistry; D002352:Carrier Proteins; D003342:Corpus Striatum / Q000378:metabolism; D004195:Disease Models, Animal; D005786:Gene Expression Regulation / Q000187:drug effects; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000493:pharmacokinetics; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D006624:Hippocampus / Q000033:anatomy & histology / Q000378:metabolism; D017403:In Situ Hybridization; D007696:Kindling, Neurologic / Q000378:metabolism*; D008297:Male; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011687:Purines / Q000378:metabolism*; D011869:Radioligand Assay / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D043705:Receptor, Adenosine A2A; D018047:Receptors, Purinergic P1 / Q000235:genetics / Q000378:metabolism*; D012640:Seizures / Q000378:metabolism*; D013460:Sulfur Isotopes / Q000493:pharmacokinetics; D014316:Tritium / Q000493:pharmacokinetics; D014970:Xanthines / Q000493:pharmacokinetics
chemical_list: D002352:Carrier Proteins; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011687:Purines; D043705:Receptor, Adenosine A2A; D018047:Receptors, Purinergic P1; D013460:Sulfur Isotopes; D014970:Xanthines; D014316:Tritium; D006165:Guanylyl Imidodiphosphate; D016244:Guanosine 5'-O-(3-Thiotriphosphate); C051360:1,3-dipropyl-8-cyclopentylxanthine; C030985:purine